ApoB
Measures the number of atherogenic lipoprotein particles in your blood — one per LDL, VLDL, and Lp(a) particle.
Optimal Range
< 80 mg/dL (optimal) · < 60 mg/dL (aggressive)
Risk-Stratified Targets
| Population / Context | Target |
|---|---|
| General populationDesirable for low-risk individuals | < 90 mg/dL |
| Moderate cardiovascular risk | < 80 mg/dL |
| High cardiovascular riskDiabetes, strong family history, multiple risk factors | < 65 mg/dL |
| Very high riskEstablished CVD, familial hypercholesterolemia, recurrent events | < 55 mg/dL |
Why It Matters
ApoB is considered by many cardiologists to be the single best predictor of cardiovascular risk — superior to LDL-C. Each particle can penetrate and deposit cholesterol in arterial walls, driving atherosclerosis.
Understanding ApoB
ApoB (apolipoprotein B) represents a paradigm shift in how we assess cardiovascular risk. Traditional cholesterol testing measures the amount of cholesterol carried within lipoproteins, but ApoB counts the actual number of atherogenic particles in your bloodstream. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule, making it a direct measure of how many particles are available to penetrate your arterial walls and initiate plaque formation.
This distinction matters because two individuals with identical LDL-C levels can have dramatically different particle counts. Someone with many small, dense LDL particles will have a higher ApoB (and higher risk) than someone with fewer, larger particles — even though their LDL-C is the same. This is called LDL-C/ApoB discordance, and it occurs in roughly 20% of the population. When LDL-C and ApoB disagree, cardiovascular risk tracks with ApoB.
The 2019 ESC/EAS guidelines formally included ApoB targets for risk management, and leading longevity physicians now consider ApoB the single best lipid marker for assessing and managing cardiovascular risk. If you only track one lipid number, many experts argue it should be ApoB.
Key Research
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review
Sniderman AD et al. · JAMA Cardiol (2019)
Key finding: ApoB is superior to LDL-C for cardiovascular risk prediction and should be adopted as the primary target for lipid-lowering therapy.
Low-density lipoproteins cause atherosclerotic cardiovascular disease: Evidence from genetic, epidemiologic, and clinical studies
Ference BA et al. · Eur Heart J (2017)
Key finding: Mendelian randomization confirms a causal, log-linear, dose-dependent relationship between ApoB-containing lipoproteins and atherosclerotic cardiovascular disease.